Trogenix announces £70M/$95M Series A financing to drive clinical development of potentially curative therapies for aggressive cancers October 7, 2025
THIO-101 Ph 2 trial to enroll patients in the U.S. as part of the expansion of the study in 3L treatment for advanced NSCLC September 30, 2025
NDA for A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC September 30, 2025
Enrollment completed in Ph 2 Combi-TED Trial of Tedopi® in Combination with Nivolumab or Docetaxel in Patients with NSCLC September 16, 2025
Asia cohort of Ph 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) + LAZCLUZE® (lazertinib) achieved statistically significant OS improvement vs osimertinib in EGFRm NSCLC September 16, 2025
Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology September 16, 2025
WCLC 2025: Final Analysis of Firmonertinib Monotherapy Data from Ph 1b Study in EGFR PACC Mutant NSCLC presented September 16, 2025
WCLC 2025: Libtayo + chemo demonstrates a more than double 5yr OS rate of 19.4% vs 8.8% with chemo alone in NSCLC September 16, 2025
WCLC 2025: Cadonilimab – Pulocimab Combo Shows Promising Results in IO-Resistant NSCLC September 16, 2025
WCLC 2025: Updated efficacy and safety data presented from Ph 2b REZILIENT1 trial of zipalertinib in EGFRm, amivantamab-ref NSCLC patients September 16, 2025
Positive efficacy data announced from Ph 2 trial of THIO-101 & cemiplimab (Libtayo®) in NSCLC patients who had failed two or more SoC therapy regimens September 16, 2025
Tagrisso + chemo demonstrated a median OS of nearly four years in global Ph 3 FLAURA2 trial in EGFR-mutated advanced NSCLC September 10, 2025
FDA grants HERNEXEOS® Breakthrough Therapy Designation in HER2 (ERBB2)m advanced 1L NSCLC September 10, 2025
WCLC 2025: New HERNEXEOS® data demonstrated promising intracranial responses in patients with advanced HER2m NSCLC with brain mets September 9, 2025
WCLC 2025: RYBREVANT® (amivantamab-vmjw) + LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in 1L EGFRm NSCLC September 9, 2025
WCLC 2025: Longer-Term Follow-Up of Patients Showed Improving, Favorable Trend in OS in Ph 3 HARMONi Clinical Trial for Ivonescimab + Chemo in 2L+ EGFRm NSCLC September 9, 2025
WCLC 2025: Interim Ph 2 Data for Pumitamig (BNT327/BMS986545) in Patients with ES-SCLC Shows Encouraging Antitumor Activity September 9, 2025
WCLC 2025: Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with ES SCLC in IDeate-Lung01 Ph 2 Trial September 9, 2025
WCLC 2025: New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive NSCLC Announced September 9, 2025
Olomorasib receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers September 9, 2025
HERNEXEOS® approved in China for previously treated patients with HER2-mutant advanced NSCLC September 3, 2025
FDA granted Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for Patients with KRAS G12C-Mutated Cancers September 3, 2025
